Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer (IMMUNOBZH)

Regional University Hospital Center (CHRU)

Status: Completed

Conditions: NSCLC

Study type: Observational

Funder types: Other

Identifiers

NCT04858204

IMMUNOBZH (29BRC17.0032)

Details and patient eligibility

About

Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice. Investigators aimed at assessing efficacy and safety of nivolumab in a real-life setting and determining a subtype of NSCLC patients that are more likely to benefit from immunotherapy.

Enrollment: 259 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• advanced NSCLC (stage IIIB-IV)
• failure of at least one line of chemotherapy.
• age ≥18 years,
• initiation of nivolumab between 01/09/2015 and 30/09/2016.

Exclusion criteria

• nivolumab initiation after October 2016
• prior involvement in an immunotherapy trial
• refusal to participate.